[go: up one dir, main page]

WO1999003488A3 - Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration - Google Patents

Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration Download PDF

Info

Publication number
WO1999003488A3
WO1999003488A3 PCT/US1998/014610 US9814610W WO9903488A3 WO 1999003488 A3 WO1999003488 A3 WO 1999003488A3 US 9814610 W US9814610 W US 9814610W WO 9903488 A3 WO9903488 A3 WO 9903488A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
peptides
reduced toxicity
animals
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/014610
Other languages
English (en)
Other versions
WO1999003488A2 (fr
Inventor
U Prasad Kari
Taffy J Williams
Michael Mclane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magainin Pharmaceuticals Inc
Original Assignee
Magainin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharmaceuticals Inc filed Critical Magainin Pharmaceuticals Inc
Priority to CA002294518A priority Critical patent/CA2294518A1/fr
Priority to AU83005/98A priority patent/AU8300598A/en
Priority to EP98933343A priority patent/EP1001800A2/fr
Priority to JP2000502785A priority patent/JP2001510164A/ja
Publication of WO1999003488A2 publication Critical patent/WO1999003488A2/fr
Publication of WO1999003488A3 publication Critical patent/WO1999003488A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des peptides biologiquement actifs à toxicité réduite et des procédés relatifs à leur élaboration. Lesdits peptides, pouvant être non substitués ou à substitution N-terminale, sont représentés par la formule (I) . Dans ladite formule, X est un peptide ou une protéine à formation de canal ionique de type amphiphile, T est une fraction lipophile ou hydrogène, et W est T ou hydrogène. De préférence, T est représenté par la formule (II). Dans ladite formule, R est hydrocarbure (alkyle ou aromatique ou alkylaromatique) ayant au moins 2 et au maximum 10 atomes de carbone. T est de préférence un groupe octanoyle. Les peptides et les protéines considérés ont une activité biologique antimicrobienne et antitumorale améliorée ainsi qu'une toxicité réduite. Le procédé préféré de réduction de la toxicité consiste à élaborer des dérivés apparentés de méthane sulfonate ou des analogues. Par ailleurs, les composés décrits peuvent être utilisés en traitement de maladie infectieuse, de choc septique, et d'infection pulmonaire, comme par exemple dans le cas de la mucoviscidose.
PCT/US1998/014610 1997-07-15 1998-07-15 Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration Ceased WO1999003488A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002294518A CA2294518A1 (fr) 1997-07-15 1998-07-15 Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration
AU83005/98A AU8300598A (en) 1997-07-15 1998-07-15 Biologically active peptides with reduced toxicity in animals and a method for preparing same
EP98933343A EP1001800A2 (fr) 1997-07-15 1998-07-15 Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration
JP2000502785A JP2001510164A (ja) 1997-07-15 1998-07-15 動物に対する毒性を減じた生物活性ペプチドおよび同ペプチドを調製する方法。

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89300697A 1997-07-15 1997-07-15
US08/893,006 1997-07-15

Publications (2)

Publication Number Publication Date
WO1999003488A2 WO1999003488A2 (fr) 1999-01-28
WO1999003488A3 true WO1999003488A3 (fr) 1999-04-08

Family

ID=25400865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014610 Ceased WO1999003488A2 (fr) 1997-07-15 1998-07-15 Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration

Country Status (5)

Country Link
EP (1) EP1001800A2 (fr)
JP (1) JP2001510164A (fr)
AU (1) AU8300598A (fr)
CA (1) CA2294518A1 (fr)
WO (1) WO1999003488A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318899B2 (en) 2008-01-24 2012-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713927B2 (en) * 2007-01-16 2010-05-11 The Regents Of The University Of California Antimicrobial peptides
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024138A1 (fr) * 1992-06-01 1993-12-09 Magainin Pharmaceuticals, Inc. Peptides biologiquement actifs presentant des substitutions n-terminales
WO1995019370A1 (fr) * 1994-01-18 1995-07-20 Magainin Pharmaceuticals Inc. Peptides amphiphiliques formant des canaux ioniques et presentant des modifications n-terminales

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024138A1 (fr) * 1992-06-01 1993-12-09 Magainin Pharmaceuticals, Inc. Peptides biologiquement actifs presentant des substitutions n-terminales
WO1995019370A1 (fr) * 1994-01-18 1995-07-20 Magainin Pharmaceuticals Inc. Peptides amphiphiliques formant des canaux ioniques et presentant des modifications n-terminales

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318899B2 (en) 2008-01-24 2012-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
US8546535B2 (en) 2008-01-24 2013-10-01 Esperance Pharmaceuticals, Inc. Lytic domain fusion constructs and methods of making and using same
US9255134B2 (en) 2008-01-24 2016-02-09 Esperance Pharmaceuticals, Inc. Lytic domain fusion constructs and methods of making and using same
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US10233214B2 (en) 2012-10-30 2019-03-19 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Also Published As

Publication number Publication date
JP2001510164A (ja) 2001-07-31
AU8300598A (en) 1999-02-10
CA2294518A1 (fr) 1999-01-28
WO1999003488A2 (fr) 1999-01-28
EP1001800A2 (fr) 2000-05-24

Similar Documents

Publication Publication Date Title
Fimland et al. New biologically active hybrid bacteriocins constructed by combining regions from various pediocin-like bacteriocins: the C-terminal region is important for determining specificity
Haug et al. The role of tryptophan in the antibacterial activity of a 15‐residue bovine lactoferricin peptide
DE69520668D1 (de) Antimikrobielle zubereitungen mit breitem spektrum und verfahren zu ihrer nutzung
AU9174398A (en) Peptides
EP1435352A3 (fr) 9-[(Glycyle substitué)amido]-6-(substitué)-5-hydroxy-6-déoxytétracyclines
PT883602E (pt) Compostos lipidicos e sua utilizacao por exemplo em lipossomas
US6329497B1 (en) Sandramycin analogs
NZ326238A (en) Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
Janiszewska et al. Low molecular mass peptide dendrimers that express antimicrobial properties
WO1999060013A3 (fr) Peptides antagonistes de il-6
WO2000002916A3 (fr) COMPOSITIONS PEPTIDIQUES IMITANT L'ACTIVITE DE TGF-$g(b)
AU4727797A (en) Microbial preparation of substances from aromatic metabolism/i
EP2248901A1 (fr) Streptogramines et procédé de préparation de streptogramines par mutasynthèse
ATE345139T1 (de) Karzinostatische wirkstoffe
WO1999003488A3 (fr) Peptides biologiquement actifs a toxicite reduite chez l'animal et procedes d'elaboration
ATE237634T1 (de) Analogen des keratinozytenwachstumfaktors
DE69722618D1 (en) Peptide
EP0161007A3 (fr) Analogues de l'hexapeptide rétro-inverso C-terminal de la substance P
Telford et al. Amonabactin: a family of novel siderophores from a pathogenic bacterium
AU5508396A (en) Pcna binding substance
AU2957099A (en) Novel physiologically active peptides and utilization thereof
PT918795E (pt) Droga antiangiogenica para tratar cancro artrite e retinopatia
Lee et al. Design and synthesis of novel antimicrobial pseudopeptides with selective membrane-perturbation activity
Koide et al. Investigation of the dimethylsulfoxide-trifluoroacetic acid oxidation system for the synthesis of cystine-containing peptides
US6677429B1 (en) Echinocandin derivatives, preparation method and application as anti-fungal agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2294518

Country of ref document: CA

Ref country code: CA

Ref document number: 2294518

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998933343

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 83005/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998933343

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998933343

Country of ref document: EP